We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
Read MoreHide Full Article
Global Blood Therapeutics, Inc. incurred a loss of $1.26 per share in first-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.29. In the year-ago quarter, the company had reported a loss of $1.21 per share.
However, the company’s revenues of $55.2 million, comprising solely Oxbryta (voxelotor) sales, missed the Zacks Consensus Estimate of $57 million. Global Blood had generated $39 million in product sales in the year-ago quarter.
Shares of Global Blood have jumped 9.8% in the year so far against the industry’s decline of 21.2%.
Image Source: Zacks Investment Research
Quarter in Details
Oxbryta sales decreased 2% sequentially driven primarily by distributors reducing inventory in the first quarter following purchases at the end of 2021 and a higher gross-to-net adjustment, partially offset by higher patient demand. The net number of patients taking Oxbryta increased from the prior quarter.
The company achieved more than 1,200 new prescriptions for Oxbryta in the first quarter. This includes a strong launch in children ages four to less than 12 years.
Research and development expenses in the reported quarter were $52.8 million, up from $59 million in the year-ago quarter, due to an increase in external costs related to the GBT601 program.
Selling, general and administrative expenses were $74.5 million in the reported quarter, up from $59 million in the year-ago quarter, due to higher employee-related costs and increased professional and consulting services’ cost.
As of Mar 31, 2022, Global Blood had cash, cash equivalents and marketable securities worth $662.1 million compared with $734.8 million as of Dec 31, 2021.
Global Blood Therapeutics, Inc. Price, Consensus and EPS Surprise
Earlier, the European Commission granted marketing authorization to Oxbryta as a monotherapy or in combination with hydroxycarbamide (hydroxyurea) for treating hemolytic anemia caused due to sickle cell disease (SCD) in adult and pediatric patients aged 12 years and above. EU’s nod is likely to boost Oxbryta sales in 2022 and beyond.
Oxbryta is approved by the FDA as an oral, once-daily treatment for SCD in patients aged 12 years or above.
In December 2021, the FDA granted accelerated approval to Global Blood’s supplemental new drug application seeking approval for Oxbryta to treat SCD in children aged four to less than 12 years.
Enrollment is ongoing in two global, randomized, placebo-controlled, pivotal phase III studies, collectively named THRIVE, evaluating the safety and efficacy of inclacumab, GBT’s P-selectin inhibitor, for the potential reduction of vaso-occlusive crisis (VOC) frequency and VOC-related hospital readmissions.
Global Blood anticipates restarting the phase I study of GBT021601 (GBT601), the company’s investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor, to study a 150 mg daily dose, which is an increase over the 100 mg daily maintenance dose previously studied. GBT is also planning to advance GBT601 into a phase II/III study and anticipates initiating the phase II portion by mid-2022.
Zacks Rank & Stocks to Consider
Global Blood currently carries a Zacks Rank #4 (Sell).
Clovis boasts a mixed track record, having topped earnings estimates in two of the last four quarters and missing in the remaining two. Clovis pulled off a four-quarter earnings surprise of 1.44%, on average.
The consensus estimate for Vertex’s 2022 earnings has increased 25 cents over the past 60 days to $14.58. Shares of VRTX have gained 24.6% in the year so far.
Loss estimates for VYGR have narrowed to $1.35 from $2.20 for 2022 in the past 60 days. Earnings of Voyager surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 41%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
Global Blood Therapeutics, Inc. incurred a loss of $1.26 per share in first-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.29. In the year-ago quarter, the company had reported a loss of $1.21 per share.
However, the company’s revenues of $55.2 million, comprising solely Oxbryta (voxelotor) sales, missed the Zacks Consensus Estimate of $57 million. Global Blood had generated $39 million in product sales in the year-ago quarter.
Shares of Global Blood have jumped 9.8% in the year so far against the industry’s decline of 21.2%.
Image Source: Zacks Investment Research
Quarter in Details
Oxbryta sales decreased 2% sequentially driven primarily by distributors reducing inventory in the first quarter following purchases at the end of 2021 and a higher gross-to-net adjustment, partially offset by higher patient demand. The net number of patients taking Oxbryta increased from the prior quarter.
The company achieved more than 1,200 new prescriptions for Oxbryta in the first quarter. This includes a strong launch in children ages four to less than 12 years.
Research and development expenses in the reported quarter were $52.8 million, up from $59 million in the year-ago quarter, due to an increase in external costs related to the GBT601 program.
Selling, general and administrative expenses were $74.5 million in the reported quarter, up from $59 million in the year-ago quarter, due to higher employee-related costs and increased professional and consulting services’ cost.
As of Mar 31, 2022, Global Blood had cash, cash equivalents and marketable securities worth $662.1 million compared with $734.8 million as of Dec 31, 2021.
Global Blood Therapeutics, Inc. Price, Consensus and EPS Surprise
Global Blood Therapeutics, Inc. price-consensus-eps-surprise-chart | Global Blood Therapeutics, Inc. Quote
Recent Updates
Earlier, the European Commission granted marketing authorization to Oxbryta as a monotherapy or in combination with hydroxycarbamide (hydroxyurea) for treating hemolytic anemia caused due to sickle cell disease (SCD) in adult and pediatric patients aged 12 years and above. EU’s nod is likely to boost Oxbryta sales in 2022 and beyond.
Oxbryta is approved by the FDA as an oral, once-daily treatment for SCD in patients aged 12 years or above.
In December 2021, the FDA granted accelerated approval to Global Blood’s supplemental new drug application seeking approval for Oxbryta to treat SCD in children aged four to less than 12 years.
Enrollment is ongoing in two global, randomized, placebo-controlled, pivotal phase III studies, collectively named THRIVE, evaluating the safety and efficacy of inclacumab, GBT’s P-selectin inhibitor, for the potential reduction of vaso-occlusive crisis (VOC) frequency and VOC-related hospital readmissions.
Global Blood anticipates restarting the phase I study of GBT021601 (GBT601), the company’s investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor, to study a 150 mg daily dose, which is an increase over the 100 mg daily maintenance dose previously studied. GBT is also planning to advance GBT601 into a phase II/III study and anticipates initiating the phase II portion by mid-2022.
Zacks Rank & Stocks to Consider
Global Blood currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Clovis Oncology , Vertex Pharmaceuticals Incorporated (VRTX - Free Report) and Voyager Therapeutics, Inc. (VYGR - Free Report) , all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clovis boasts a mixed track record, having topped earnings estimates in two of the last four quarters and missing in the remaining two. Clovis pulled off a four-quarter earnings surprise of 1.44%, on average.
The consensus estimate for Vertex’s 2022 earnings has increased 25 cents over the past 60 days to $14.58. Shares of VRTX have gained 24.6% in the year so far.
Loss estimates for VYGR have narrowed to $1.35 from $2.20 for 2022 in the past 60 days. Earnings of Voyager surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 41%.